How Cambridge Companies Are Supporting Cell and Gene Therapy

Cell and gene therapy development depends on more than therapeutic developers alone. It needs engineered cell platforms, gene editing tools, safety assays, translational biology and manufacturing support that can help products move from early research into clinical development.

Around Cambridge, several companies are working on different parts of that chain. Some are developing programmable cells or reprogramming approaches. Others are helping developers understand editing outcomes, cell behaviour or GMP manufacturing needs. Together, they show how the Cambridge-area ecosystem supports advanced therapies from several directions.

This is a selected Benchscope guide, not an exhaustive ranking. Companies are included based on their stated services, location, relevance to the topic and presence within the Benchscope life sciences dataset.

Xap Therapeutics

Xap Therapeutics is based at Babraham Research Campus near Cambridge and develops programmable cell therapies using genome editing and synthetic biology. Its platform is built around a modular chassis cell that can be armed with therapeutic payloads, including cytokines, antibodies and nucleic acids.

The company describes these delivery vehicles as activating when they recognise selected disease targets. For cell and gene therapy developers, Xap sits close to the therapeutic design end of the field, with programmes directed towards cancer and autoimmune disease.

View Xap Therapeutics on Benchscope →

Intima Bioscience

Intima Bioscience is a clinical-stage oncology company with a Cambridge UK presence. Its public materials focus on CISH, an intracellular immune checkpoint involved in T cell function, including small molecule checkpoint inhibition and CRISPR-engineered CISH-knockout T cell clinical work.

In 2025, Intima presented first-in-human data from CISH-knockout tumour-infiltrating lymphocytes in metastatic colorectal cancer at AACR. The company’s work is relevant to this guide because it connects tumour-infiltrating lymphocyte biology, gene editing and immuno-oncology, while sitting at the boundary between cell therapy research and drug discovery.

View Intima Bioscience on Benchscope →

Mogrify

Mogrify is based at Cambridge Science Park and develops in vivo cellular reprogramming therapies for degenerative diseases. Rather than manufacturing a therapeutic cell outside the body, its approach is designed to identify transcriptomic and epigenetic switches that could convert mature cells into therapeutic cell types directly in the body.

The company’s stated areas include otology, ophthalmology and diabetes, with partnering interest across regenerative medicine and related cell-based therapies. Mogrify adds a different angle to this guide because it is focused on changing cell identity rather than only transplanting or engineering cells ex vivo.

View Mogrify on Benchscope →

Broken String Biosciences

Broken String Biosciences is based at Chesterford Research Park near Cambridge and provides tools for gene editing safety analysis. Its BreakMap platform, powered by INDUCE-seq, is designed to map genome-wide on-target and off-target DNA breaks in relevant cell systems.

The company says its workflow supports guide screening, optimisation and downstream characterisation as programmes move from discovery towards development. In April 2026, Broken String announced an FDA Master File submission for INDUCE-seq, adding a current regulatory-support detail to its gene editing safety work.

View Broken String Biosciences on Benchscope →

Advent BioServices

Advent BioServices is a cell therapy development and manufacturing organisation operating GMP facilities at Sawston, Cambridgeshire. The company is now part of Northwest Biotherapeutics, following an acquisition that closed in October 2025.

Advent’s Sawston facility supports cell therapy development, GMP manufacturing, quality control and cryostorage, including work linked to NWBio’s DCVax platform. Advent adds a manufacturing layer to this guide, showing how the Cambridge area supports not only therapeutic design and safety analysis, but also the practical work needed to move cell therapy programmes towards clinical supply.

View Advent BioServices on Benchscope →

Wider view

These companies show that Cambridge-area cell and gene therapy activity is spread across several linked problems. Xap and Intima sit closer to engineered therapeutic cells. Mogrify approaches the field through in vivo reprogramming. Broken String supports gene editing safety analysis, while Advent BioServices provides GMP manufacturing and storage capacity.

That spread matters because cell and gene therapy development is not a single task. Target selection, editing, potency, safety, process design, manufacturing and translational evidence all need specialist input before products can move confidently through development.

Browse other Cell & Gene Therapy organisations listed on Benchscope, or explore more life science companies by location, category and focus area. Benchscope is building a clearer map of the UK life sciences sector. If your company is listed and would like to update your profile, or if you think we have missed a relevant organisation, submit an update here.